Skip to main content
. 2018 Aug 21;10(9):279. doi: 10.3390/cancers10090279

Figure 3.

Figure 3

Kaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) according to the DNA mismatch repair (MMR) immunohistochemistry (IHC) status and MLH1 promotor methylation status for endometrial cancer. PFS (A) and OS (B) in the MMR-deficient vs the MMR-proficient group. PFS (C) and OS (D) in the sporadic cancer vs the PLS group. Comparison of PFS (E) and OS (F) in the sporadic cancer group between those with MMR deficiency with MLH1 methylation and those with MMR proficiency. PFS (G) and OS (H) of the MMR-deficient vs the MMR proficient group in the patients with FIGO stages I–II.